{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=29&state=Ohio", "query": { "state": "Ohio", "city": "Columbus", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 10851, "total_pages": 1086, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=30&state=Ohio&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Columbus&page=28&state=Ohio&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T22:00:37.024Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02592798", "title": "Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nephrotic Syndrome", "Focal Segmental Glomerulosclerosis", "Minimal Change Disease" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Normal Saline", "type": "OTHER" }, { "name": "D5W", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 36, "start_date": "2016-03-09", "completion_date": "2020-01-28", "has_results": true, "last_update_posted_date": "2021-03-05", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02592798" }, { "nct_id": "NCT04905693", "title": "Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Pulmonary Fibrosis", "Interstitial Lung Disease", "Progressive Pulmonary Fibrosis" ], "interventions": [ { "name": "Inhaled Treprostinil", "type": "DRUG" }, { "name": "Treprostinil Ultrasonic Nebulizer", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "United Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 1850, "start_date": "2022-09-06", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 81, "location_summary": "Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Franklin", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04905693" }, { "nct_id": "NCT00026221", "title": "Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Skin Melanoma" ], "interventions": [ { "name": "Recombinant Interferon Alfa", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2001-11", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2016-03-17", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 2, "location_summary": "Cincinnati, Ohio • Columbus, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026221" }, { "nct_id": "NCT03739814", "title": "Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative", "Recurrent B Acute Lymphoblastic Leukemia", "Refractory B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Inotuzumab Ozogamicin", "type": "BIOLOGICAL" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Ponatinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 84, "start_date": "2019-05-08", "completion_date": "2027-02-01", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 283, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 175 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03739814" }, { "nct_id": "NCT02582684", "title": "Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "Dolutegravir", "type": "DRUG" }, { "name": "Lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2015-12-08", "completion_date": "2017-09-26", "has_results": true, "last_update_posted_date": "2018-05-09", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 25, "location_summary": "Los Angeles, California • San Diego, California • Torrance, California + 17 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02582684" }, { "nct_id": "NCT07700433", "title": "Safety and Efficacy of the BTL-043 and BTL-899 Devices in Alleviating Back Pain", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Back Pain" ], "interventions": [ { "name": "Treatment with BTL-043", "type": "DEVICE" }, { "name": "BTL-899", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "BTL Industries Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 60, "start_date": "2025-12-08", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Fort Myers, Florida • Columbus, Ohio + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Wichita Falls", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07700433" }, { "nct_id": "NCT02728804", "title": "S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Stage IVA Colon Cancer", "Stage IVA Rectal Cancer", "Stage IVB Colon Cancer", "Stage IVB Rectal Cancer" ], "interventions": [ { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2016-06-22", "completion_date": "2020-11-13", "has_results": true, "last_update_posted_date": "2023-01-26", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 537, "location_summary": "Anchorage, Alaska • Hot Springs, Arkansas • Antioch, California + 343 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02728804" }, { "nct_id": "NCT03927833", "title": "Cycled Phototherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hyper Bilirubinemia", "Premature Infant" ], "interventions": [ { "name": "Phototherapy lights", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "NICHD Neonatal Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Weeks", "maximum_age": "27 Weeks", "sex": "ALL", "summary": "22 Weeks to 27 Weeks" }, "enrollment_count": 1700, "start_date": "2020-07-16", "completion_date": "2027-07-31", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03927833" }, { "nct_id": "NCT00937352", "title": "A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Bapineuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "JANSSEN Alzheimer Immunotherapy Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "51 Years", "maximum_age": null, "sex": "ALL", "summary": "51 Years and older" }, "enrollment_count": 896, "start_date": "2009-07", "completion_date": "2012-09", "has_results": false, "last_update_posted_date": "2013-12-20", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 176, "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 140 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00937352" }, { "nct_id": "NCT00644943", "title": "A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Amoxicillin/Clavulanate in Pediatric Subjects With Acute Otitis Media", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Acute Otitis Media" ], "interventions": [ { "name": "cefdinir (Omnicef)", "type": "DRUG" }, { "name": "amoxicillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "6 Years", "sex": "ALL", "summary": "6 Months to 6 Years" }, "enrollment_count": 425, "start_date": "2003-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2008-03-27", "last_synced_at": "2026-11-04T22:00:37.024Z", "location_count": 32, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Ozark, Alabama + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Ozark", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00644943" } ] }